Envoy Medical (COCH) Registration filing summary

Company overview and business model

• Focuses on innovative, fully implanted hearing devices leveraging natural ear anatomy, with the Acclaim CI as the lead product candidate targeting severe to profound sensorineural hearing loss in adults.

• The Acclaim CI is designed to disrupt the cochlear implant market by eliminating external components and leveraging a sensor-based approach.

• The company’s first product, Esteem FI-AMEI, is FDA-approved but saw limited commercial success due to lack of reimbursement; efforts are ongoing to reclassify it for better coverage.

• Business model relies on obtaining regulatory approval, establishing reimbursement, and building strategic relationships with surgical sites and audiologists.

• Plans for international expansion post-FDA approval, with a focus on the U.S. market initially.

Financial performance and metrics

• Reported net losses of $20.8 million in 2024 and $10.7 million for the six months ended June 30, 2025; accumulated deficit of $297.9 million as of June 30, 2025.

• Revenue remains minimal, primarily from legacy Esteem FI-AMEI sales and replacements; no revenue yet from Acclaim CI.

• R&D expenses increased to $10.2 million in 2024, reflecting clinical trial activity and headcount growth.

• Cash balance was $5.3 million as of June 30, 2025; company expects to need additional capital to fund operations beyond September 2025.

• Substantial doubt exists about the company’s ability to continue as a going concern without further financing.

Use of proceeds and capital allocation

• Proceeds from recent offerings and warrant exercises are intended for working capital and general corporate purposes.

• If all warrants are exercised for cash, gross proceeds could total approximately $20.1 million.

• Capital allocation priorities include R&D, regulatory activities, commercialization infrastructure, and expansion of manufacturing capacity.